213
Participants
Start Date
January 23, 2014
Primary Completion Date
March 31, 2017
Study Completion Date
September 30, 2017
Survey
Patients will report pain and analgesic use through the automated telephone system, for 7 days in a row, once every 6 weeks. Data from diagnostic tests (CT Abdomen/Pelvis, Bone Scan, PSA, and circulating tumor cells) conducted during the study period will be collected from medical records by local personnel and entered into the secure online database quarterly, but no specific tests or schedules will be required in this observational study. Patients will remain on study for up to 26 months (slightly longer than the expected median survival in this population based on data from docetaxel, abiraterone, and MDV3100 pivotal phase 3 trials).
Johns Hopkins University, Baltimore
Lineberger Comprehensive Cancer Center, Chapel Hill
Oregon Health and Science University, Portland
University of Washington, Seattle
United States Department of Defense
FED
Memorial Sloan Kettering Cancer Center
OTHER
Johns Hopkins University
OTHER
University of Washington
OTHER
Oregon Health and Science University
OTHER
UNC Lineberger Comprehensive Cancer Center
OTHER